Basis: Trailing twelve months (TTM net income over the latest quarterly balance sheet). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the return on assets (ROA) high or low?
The return on assets (ROA) of -79.38% is 77% below its 5-year average of -44.84%, near the low end of its 5-year range (-166.84%–161.54%).
290.68% below its 12-month average of 41.63%.
Reported quarterly return on assets; no daily interpolation. Q2 FY2026 (2026-06-30): -22.99%.
RETURN ON ASSETS (ROA)
-79.38%
RETURN ON ASSETS (ROA) AVG TTM
41.63%
RETURN ON ASSETS (ROA) AVG 3Y
-36.06%
RETURN ON ASSETS (ROA) AVG 5Y
-44.84%
RETURN ON ASSETS (ROA) AVG 10Y
-178.81%
RETURN ON ASSETS (ROA) AVG 15Y
N/A
RETURN ON ASSETS (ROA) AVG 20Y
N/A
CURRENT VS TTM AVG
-290.68%
CURRENT VS 3Y AVG
-120.15%
CURRENT VS 5Y AVG
-77.04%
CURRENT VS 10Y AVG
+55.61%
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
-28.05%
median of 558 covered companies
CURRENT VS SECTOR MEDIAN
-183.05%
vs the sector median at left
Atara Biotherapeutics, Inc.
Market Cap
$84.52M
Return on Assets (ROA)
-79.38%
TTM Avg
41.63%
3Y Avg
-36.06%
5Y Avg
-44.84%
Market Cap
$81.67M
Return on Assets (ROA)
49.88%
TTM Avg
-47.68%
3Y Avg
-37.92%
5Y Avg
-34.36%
Market Cap
$81.31M
Return on Assets (ROA)
-41.94%
TTM Avg
-38.20%
3Y Avg
-35.26%
5Y Avg
-28.99%
Market Cap
$81.82M
Return on Assets (ROA)
-41.09%
TTM Avg
-24.80%
3Y Avg
-25.41%
5Y Avg
-25.41%
Market Cap
$80.49M
Return on Assets (ROA)
-136.52%
TTM Avg
-104.53%
3Y Avg
-92.09%
5Y Avg
-76.74%
Market Cap
$84.17M
Return on Assets (ROA)
-26.59%
TTM Avg
-23.05%
3Y Avg
-19.50%
5Y Avg
-17.99%
Market Cap
$84.87M
Return on Assets (ROA)
-70.05%
TTM Avg
-71.47%
3Y Avg
-58.80%
5Y Avg
-51.13%
Market Cap
$85.90M
Return on Assets (ROA)
-43.13%
TTM Avg
-80.45%
3Y Avg
-58.18%
5Y Avg
-65.67%
Market Cap
$85.18M
Return on Assets (ROA)
-74.91%
TTM Avg
-50.52%
3Y Avg
-40.48%
5Y Avg
-70.00%
| NAME | MARKET CAP | RETURN ON ASSETS (ROA) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Atara Biotherapeutics, Inc. (ATRA) | $84.52M | -79.38% | 41.63% | -36.06% | -44.84% |
| LENSAR Inc (LNSR)vs › | $81.67M | 49.88% | -47.68% | -37.92% | -34.36% |
| Pulmonx Corporation (LUNG)vs › | $81.31M | -41.94% | -38.20% | -35.26% | -28.99% |
| Citius Oncology, Inc. (CTOR)vs › | $81.82M | -41.09% | -24.80% | -25.41% | -25.41% |
| Inovio Pharmaceuticals, Inc. (INO)vs › | $80.49M | -136.52% | -104.53% | -92.09% | -76.74% |
| MediciNova, Inc. (MNOV)vs › | $84.17M | -26.59% | -23.05% | -19.50% | -17.99% |
| Humacyte, Inc. (HUMA)vs › | $84.87M | -70.05% | -71.47% | -58.80% | -51.13% |
| Cognition Therapeutics, Inc. (CGTX)vs › | $85.90M | -43.13% | -80.45% | -58.18% | -65.67% |
| Acrivon Therapeutics, Inc. Common Stock (ACRV)vs › | $85.18M | -74.91% | -50.52% | -40.48% | -70.00% |
| MindWalk Holdings Corp. (HYFT)vs › | $75.58M | -99.89% | -66.19% | -52.51% | -39.81% |
ROA
-79.4%
ROE
N/A
ROA = Net Income / Total Assets
Return on assets measures how efficiently a company generates profit from its total assets.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | RETURN ON ASSETS (ROA) |
|---|---|
| 2025-12-31 | 161.54% |
| 2024-12-31 | -78.28% |
| 2023-12-31 | -166.84% |
| 2022-12-31 | -60.65% |
| 2021-12-31 | -72.66% |
| 2020-12-31 | -52.14% |
| 2019-12-31 | -84.85% |
| 2018-12-31 | -588.76% |
| 2017-12-31 | -548.68% |
| 2016-12-31 | -299.53% |
| 2015-12-31 | -176.08% |
| 2014-12-31 | -263.90% |
| 2013-12-31 | -169.27% |
| 2012-12-31 | -2874.13% |
